BLUE bluebird bio Inc

Price (delayed)

$28.21

Market cap

$1.89B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.95

Enterprise value

$1.77B

Sector: Healthcare
Industry: Biotechnology

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights

The EPS has increased by 30% year-on-year and by 9% since the previous quarter
The company's net income rose by 22% YoY and by 3.7% QoQ
The quick ratio has grown by 16% YoY but it has contracted by 9% from the previous quarter
bluebird bio's equity has decreased by 11% from the previous quarter but it has increased by 5% YoY

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
67.14M
Market cap
$1.89B
Enterprise value
$1.77B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.06
Earnings
Revenue
$250.73M
EBIT
-$629.55M
EBITDA
-$610.19M
Free cash flow
-$499.34M
Per share
EPS
-$9.95
Free cash flow per share
-$8.03
Book value per share
$20.42
Revenue per share
$4.03
TBVPS
$28.28
Balance sheet
Total assets
$1.78B
Total liabilities
$426.2M
Debt
$193.02M
Equity
$1.36B
Working capital
$1.01B
Liquidity
Debt to equity
0.14
Current ratio
5.97
Quick ratio
5.79
Net debt/EBITDA
0.2
Margins
EBITDA margin
-243.4%
Gross margin
97.8%
Net margin
-246.8%
Operating margin
-251.1%
Efficiency
Return on assets
-33.6%
Return on equity
-43.6%
Return on invested capital
-49.6%
Return on capital employed
-39.9%
Return on sales
-251.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
8.83%
1 week
4.68%
1 month
-41.35%
1 year
-61.2%
YTD
-34.8%
QTD
-34.8%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
$250.73M
Gross profit
$245.34M
Operating income
-$629.51M
Net income
-$618.7M
Gross margin
97.8%
Net margin
-246.8%
BLUE's operating margin has surged by 86% year-on-year and by 4% since the previous quarter
bluebird bio's net margin has soared by 86% YoY and by 3.9% from the previous quarter
bluebird bio's operating income has increased by 22% YoY and by 3.7% from the previous quarter
The company's net income rose by 22% YoY and by 3.7% QoQ

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
1.38
P/S
7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.06
The EPS has increased by 30% year-on-year and by 9% since the previous quarter
BLUE's P/B is 62% below its 5-year quarterly average of 3.6 and 37% below its last 4 quarters average of 2.2
bluebird bio's equity has decreased by 11% from the previous quarter but it has increased by 5% YoY
BLUE's P/S is 96% below its 5-year quarterly average of 170.7 and 68% below its last 4 quarters average of 21.9

Efficiency

How efficient is bluebird bio business performance
The return on sales has surged by 86% year-on-year and by 4.7% since the previous quarter
bluebird bio's ROA has increased by 17% YoY and by 4.3% from the previous quarter
bluebird bio's ROE has increased by 15% YoY and by 4.8% from the previous quarter
bluebird bio's return on invested capital has increased by 6% QoQ

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The current ratio has grown by 16% YoY but it has contracted by 9% from the previous quarter
The quick ratio has grown by 16% YoY but it has contracted by 9% from the previous quarter
bluebird bio's debt is 86% less than its equity
bluebird bio's equity has decreased by 11% from the previous quarter but it has increased by 5% YoY
BLUE's debt to equity is up by 8% since the previous quarter but it is down by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.